TYROSINE KINASE INHIBITORS (TKI) FOR THE TREATMENT OF ADVANCED MEDULLARY THYROID CARCINOMA: A SYSTEMATIC REVIEW AND INDIRECT COMPARISON

被引：0
|
作者：
Kawalec, P. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：A708 / A708
页数：1
相关论文
共 50 条
  • [31] A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma
    Chan, Abigail Sy
    Pond, Gregory Russell
    Sonpavde, Guru
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma
    Bianchi, Loredana
    Rossi, Luigi
    Tomao, Federica
    Papa, Anselmo
    Zoratto, Federica
    Tomao, Silverio
    ENDOCRINE-RELATED CANCER, 2013, 20 (05) : R233 - R245
  • [33] Analysis of resistant mechanisms for tyrosine kinase inhibitors in thyroid carcinoma
    Koichi, Ohno
    Shibata, Tomohiro
    Ito, Kenichi
    CANCER SCIENCE, 2022, 113 : 1048 - 1048
  • [34] Long term exposure to tyrosine kinase inhibitors (TKI): case report and review
    Quintyne, K. I.
    Calvert, P. M.
    LUNG CANCER, 2009, 63 : S3 - S3
  • [35] Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma
    Montgomery, Jim
    Garofalo, David
    Drenning, Jason
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
    Jolanta Krajewska
    Aleksandra Kukulska
    Ewa Paliczka-Cieślik
    Daria Handkiewicz-Junak
    Tomasz Gawlik
    Tomasz Olczyk
    Aleksandra Kropińska
    Aleksander Skoczylas
    Barbara Michalik
    Barbara Jarząb
    Thyroid Research, 6 (Suppl 2)
  • [37] The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
    Ntanasis-Stathopoulos, Ioannis
    Fotopoulos, George
    Tzanninis, Ioannis-Georgios
    Kotteas, Elias A.
    CANCER INVESTIGATION, 2016, 34 (07) : 313 - 339
  • [38] Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis
    Hesselink, E. N. Klein
    Steenvoorden, D.
    Kapiteijn, E.
    Corssmit, E. P.
    van der Horst-Schrivers, A. N. A.
    Lefrandt, J. D.
    Links, T. P.
    Dekkers, O. M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (05) : R215 - R225
  • [39] Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
    Lorusso, Loredana
    Pieruzzi, Letizia
    Biagini, Agnese
    Sabini, Elena
    Valerio, Laura
    Giani, Carlotta
    Passannanti, Paolo
    Pontillo-Contillo, Benedetta
    Battaglia, Valentina
    Mazzeo, Salvatore
    Molinaro, Eleonora
    Elisei, Rossella
    ONCOTARGETS AND THERAPY, 2016, 9 : 6467 - 6477
  • [40] Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma
    Shankar, Ananth
    Kurzawinski, Tom
    Ross, Emma
    Stoneham, Sara
    Beale, Tim
    Proctor, Ian
    Hulse, Tony
    Simpson, Kate
    Gaze, Mark N.
    Cattaneo, Elene
    Gevers, Evelien
    Marshall, Lynley
    Hubbard, Johnathan G.
    Brain, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 158 : 38 - 46
12345